Join the Pain group to help and get support from people like you.
Pain News (Page 6)
FDA Medwatch Alert: Morphine Sulfate 0.5 mg/mL Preservative Free in 0.9 percent Sodium Chloride by by Pharmakon Pharmaceuticals: Recall - Super-potent Product
ISSUE: FDA is alerting health care professionals of a voluntary recall of morphine sulfate 0.5 mg/mL preservative free in 0.9% sodium chloride, 1 mL syringe, CII, for intravenous use made and...
FDA Approves Belbuca (buprenorphine) Buccal Film for Chronic Pain Management
DUBLIN and RALEIGH, N.C., October 26, 2015 – Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), and BioDelivery Sciences International, Inc. (NASDAQ: BDSI),...
FDA Approves MorphaBond (morphine sulfate) Extended-Release Tablets with Abuse-Deterrent Properties
VALLEY COTTAGE, N.Y., Oct. 5, 2015 /PRNewswire/ – Inspirion Delivery Technologies LLC (“Inspirion”) announced that the United States Food and Drug Administration (FDA) has approved MorphaBond™ (morphi...
FDA Medwatch Alert: Tramadol: Drug Safety Communication - FDA Evaluating Risks of Using in Children Aged 17 and Younger
ISSUE: FDA is investigating the use of the pain medicine tramadol in children aged 17 years and younger, because of the rare but serious risk of slowed or difficult breathing. This risk may be ...
FDA Approves Oxycontin (oxycodone) for Children as Young as 11
FRIDAY, Aug. 14, 2015 – Limited use of the widely abused painkiller OxyContin in children as young as 11 years old was approved by the U.S. Food and Drug Administration. Studies by OxyContin maker...
Zogenix Receives FDA Approval for New Abuse-Deterrent Formulation of Zohydro ER
SAN DIEGO, Jan. 30, 2015 – Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, today announced...
FDA Medwatch Alert: Prescription and Over-the-Counter (OTC) Pain Medicines: Drug Safety Communication - FDA Review of Possible Risks of Pain Medicine Use During Pregnancy
[Posted 01/09/2015] ISSUE: FDA is aware of and understands the concerns arising from recent reports questioning the safety of prescription and over-the-counter (OTC) pain medicines when used ...
Hospira Receives U.S. FDA Approval of Proprietary Analgesic Dyloject (diclofenac sodium) Injection
LAKE FOREST, Ill., Dec. 30, 2014 /PRNewswire/ – Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has...
FDA Approves Hysingla ER - Extended-Release Hydrocodone with Abuse-Deterrent Properties
November 20, 2014 – The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily,...
FDA Medwatch Alert: Assured Brand Naproxen Sodium Tablets by Contract Packaging Resources, Inc.: Recall - Packaging Mix-Up
ISSUE: Contract Packaging Resources, a drug repackaging company, is voluntarily recalling 11,640 boxes of Assured brand Naproxen Sodium tablets because some cartons actually contain bottles of...
FDA Approves Labeling with Abuse-Deterrent Features for Embeda (morphine/naltrexone)
October 17, 2014 – The U.S. Food and Drug Administration today approved new labeling for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, an opioid analgesic to...
FDA Medwatch Alert: Ketorolac Tromethamine Injection, USP, 30mg/ml by Sagent Pharmaceuticals: Recall - Incorrect Labeling
ISSUE: Sagent Pharmaceuticals, Inc. issued a voluntary nationwide recall of three lots (lot numbers: MP5021, MP5024 and MP5025) of Ketorolac Tromethamine Injection, USP, 30mg/mL single-dose vials...
Iroko Pharmaceuticals Gains FDA Approval of Zorvolex for Management of Osteoarthritis Pain
PHILADELPHIA, August 25, 2014 — Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today the United States Food and Drug A...
FDA Approves Targiniq ER Extended-Release Oxycodone with Abuse-Deterrent Properties
July 23, 2014 – Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting...
FDA Medwatch Alert: Epidural Corticosteroid Injection: Drug Safety Communication - Risk of Rare But Serious Neurologic Problems
Including methylprednisolone, hydrocortisone, triamcinolone, betamethasone, and dexamethasone [Posted 04/23/2014] ISSUE: FDA is warning that injection of corticosteroids into the epidural space of...
Further information
Related condition support groups
Chronic Pain, Back Pain, Fibromyalgia, Headache, Muscle Pain, Neuralgia, Neck Pain, Chronic Myofascial Pain, Nocturnal Leg Cramps, Reflex Sympathetic Dystrophy Syndrome, Breakthrough Pain
Related drug support groups
gabapentin, tramadol, ibuprofen, oxycodone, Tylenol, hydrocodone, naproxen, acetaminophen, meloxicam, view more... amitriptyline, aspirin, Percocet, hydroxyzine, Norco, pregabalin, duloxetine, diclofenac, methadone, codeine, OxyContin, cyclobenzaprine, Vicodin, Celebrex, Aleve, fentanyl, Advil, Voltaren, morphine, clonidine, buprenorphine, Paracetamol Teva, nortriptyline, Paracetamol, Butrans, Motrin, cannabis, Dilaudid, Tylenol PM, indomethacin, Toradol, Ultram, Lortab, Vistaril, acetaminophen / hydrocodone, ketamine, Roxicodone, Arthritis Pain, ketorolac, Atarax, Percocet 10/325, hydromorphone, Nucynta, Belbuca